Most Read Articles
01 Oct 2015
BLACKMORES ESSENTIAL LIVO – Phosphatidylcholine, Zinc and Chromium Capsules
13 Dec 2016
Any abnormal decrease in a person’s usual bowel movement frequency and/or pain during stool passage is termed as Constipation.
Roshini Claire Anthony, 6 days ago

The incidence of cardiovascular events in the first year following a primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) is comparable between patients given prasugrel and ticagrelor post-surgery, according to results of the PRAGUE-18* trial presented at AHA 2017.

Roshini Claire Anthony, 08 Nov 2017

The presence of vitreous haze, snow banking, and choroidal involvement is associated with an increased risk of antitubercular treatment failure in patients with tubercular (TB) uveitis, according to research by the COTS-1* Study Group.

Withdrawal due to adverse events higher with nalmefene

02 Sep 2017

Patients receiving nalmefene to treat impulse control disorders or substance use suffer from a threefold greater risk of withdrawal because of adverse safety events, according to a new meta-analysis.

The meta-analysis included eight randomized controlled trials (RCTs), of which only six reported serious adverse events (SAEs). There was no significant difference in SAE between the nalmefene and placebo groups (Peto odds ratio [POR], 0.97; 95 percent CI, 0.64 to 1.44; p=0.86; risk difference [RD], -0.00; -0.02 to -0.01; p=0.84).

Similarly, the odds for overall psychiatric SAEs were not significantly different between the nalmefene and placebo groups (POR, 1.32; 0.62 to 2.38; p=0.47; RD, 0.00; -0.01 to 0.01; p=0.40). There were also no differences in the risk of depression, anxiety or death.

Pooled findings from all eight RCTs showed that withdrawals due to adverse events were significantly higher in the nalmefene group than in the placebo group (POR, 3.22; 2.46 to 4.22; p<0.00; RD, 0.09; 0.08 to 0.11; p=0.00).

RCTs were included in the meta-analysis if they compared nalmefene to placebo or active controls in patients with impulse control and/or substance use disorders. Those with data on harms were included.

The databases of PubMed, Medline, Embase, Clinicaltrials.gov and the Cochrane Central Register of Controlled Trials were accessed.

Fifteen studies fulfilled the eligibility criteria and only eight were included in the final analysis because of missing harms data. Of the 15 studies, two were still ongoing. The remaining 13 studies corresponded to 3,793 participants.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2015
BLACKMORES ESSENTIAL LIVO – Phosphatidylcholine, Zinc and Chromium Capsules
13 Dec 2016
Any abnormal decrease in a person’s usual bowel movement frequency and/or pain during stool passage is termed as Constipation.
Roshini Claire Anthony, 6 days ago

The incidence of cardiovascular events in the first year following a primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) is comparable between patients given prasugrel and ticagrelor post-surgery, according to results of the PRAGUE-18* trial presented at AHA 2017.

Roshini Claire Anthony, 08 Nov 2017

The presence of vitreous haze, snow banking, and choroidal involvement is associated with an increased risk of antitubercular treatment failure in patients with tubercular (TB) uveitis, according to research by the COTS-1* Study Group.